Iniciar sesión

 

Mico pLung

Participantes

No hay participantes

Innovating Works @ Copyright . Todos los derechos reservados. | Política de Cookies |  Términos y Condiciones de uso |  Política de privacidad |  Aviso Legal |  Todas las Ayudas |  Todas las Empresas

Fecha
Inicio: 01/07/2013, Fin: 31/12/2014.

Objetivos
Objetivos del proyecto The use of Mycoplasma pneumoniae or its closest relative M. genitalium engineered for the controlled delivery of therapeutic peptides or proteins in situ, i.e. where they currently reside, could open new possibilities for the treatment of lung and genital tract diseases.Taking advantage of the parasite nature of M. pneumoniae to lung tissue, we plan to use genetically engineered forms of this bacterium for the local, and eventually conditional de... The use of Mycoplasma pneumoniae or its closest relative M. genitalium engineered for the controlled delivery of therapeutic peptides or proteins in situ, i.e. where they currently reside, could open new possibilities for the treatment of lung and genital tract diseases.Taking advantage of the parasite nature of M. pneumoniae to lung tissue, we plan to use genetically engineered forms of this bacterium for the local, and eventually conditional delivery of therapeutic proteins in the context of distinct and many times highly invalidating respiratory disorders, as a proof-of-concept of a new technology platform.Results of the work done at the CRG on the two projects above shall be validated in vitro and in vivo and, if successful, constitute the basis for a licensing agreement, or eventually a spin-off company created to bring the engineered bacteria or modifications thereof into the clinic. Interestingly, additional applications could be proposed at some point to diseases of the genital tract using engineered M. genitalium as a living vector. ver más

Ambito
Comunidad autónoma: Se buscaba un proyecto en cooperación con un partner de CCAA especificas.

Este proyecto fue tramitado con éxito!.